Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes

Medical Decision Making

Volumn 19, Issue 2, 1999, Pages 113-121

  Mackeigan, Linda D ^a   O'Brien, Bernie J ^b   Oh, Paul I ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Diabetes; Individual preferences; QALYs; Treatment paths

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; QUALITY ADJUSTED LIFE YEAR;

ADULT; AGED; AGED, 80 AND OVER; CHOICE BEHAVIOR; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEASIBILITY STUDIES; HOLISTIC HEALTH; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PATIENT SATISFACTION; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032982239     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X9901900201     Document Type: Article

References (25)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
2. Bleichrodt H, Johannesson M. The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence. Med Decis Making. 1997;17:21-32.
3. Johannesson M. The ranking properties of healthy-year equivalents and quality-adjusted life-years under certainty and uncertainty. Int J Technol Assess Health Care. 1995;11: 40-8.
4. Johannesson M, Pliskin JS, Weinstein MC. Are healthy-year equivalents an improvement over quality-adjusted life years? Med Decis Making. 1993;13:281-92.
5. Richardson J, Hall J, Salkfeld G. The measurement of utility in multiphase health states. Int J Technol Assess Health Care. 1996;12:151-62.
6. Kupperman M, Shiboski S, Feeny D, Elkin EP, Washington E. Can preference scores for discrete states be used to derive preference scores for an entire path of events? Med Decis Making. 1997;42:42-55.
7. Krabbe PFM, Bonsel GJ. Sequence effects, health profiles, and the QALY model. Med Decis Making. 1998;18:178-86.
8. MacKeigan LD, Oh PI, O'Brien BJ, Leiter LA. Economic evaluation of acarbose in the treatment of type 2 diabetes in Canada (forthcoming).
9. Furlong W, Feeny D, Torrance GS, Barr R, Horsman J. Guide to Design and Development of Health-state Utility Instrumentation. CHEPA Working Paper Series No. 90-9. Hamilton, Ontario, Canada: McMaster University, 1990.
10. Roper Starch Market Research. 1994 Canadian oral hypoglycemie market. Roper Starch Market Research, New York, 1995.
11. Ross SA, Fick GH. Early detection of diabetic retinopathy: the southern Alberta study of diabetic retinopathy. No. 6609-1386-53. National Health Research and Development Program. Health and Welfare Canada, Ottawa, Ontario, 1992.
12. Metropolitan Life Insurance. Life expectancy among diabetics in the United States. Metropolitan Life Statistical Bulletin. 1979;60:6-8.
13. Canadian Diabetes Advisory Board. Clinical practice guidelines for treatment of diabetes mellitus. Can Med Assoc J. 1992;147:697-712.
14. Canadian drugstore and hospital purchases. Toronto, Ontario, Canada: Intercontinental Medical Statistics (IMS), 1995.
15. Torrance GW. Measurement of health state utilities for economics appraisal. J Health Econ. 1986;5:1-30.
16. Johannesson M. QALYs, HYEs and individual preferences - A graphical illustration. Soc Sci Med. 1994;39:1623-32.
17. Wakker PP. A criticism of healthy-years equivalents. Med Decis Making. 1996;16:207-14.
18. Morrison GC. HYE and TTO: what is the difference? J Health Econ. 1997;16:563-78.
19. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989;9: 142-9.
20. Kramer MS, Feinstein AR. Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther. 1981;29:111-23.
21. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science. 1981;211:453-8.
22. Loewenstein GF, Prelec D. Preferences for sequences of outcomes. Psychol Rev. 1993;100:91-1008.
23. Fowler FJ, Cleary PD, Massagli MP, Weissman J, Epstein A. The role of reluctance to give up life in the management of values of health states. Med Decis Making. 1995;15:195-9.
24. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam health outcomes study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
25. Evans WJ, Cayton CG, Green PA. Determining the generalizability of rating scales in clinical settings. Med Care. 1981; 19:1211-20.